Extended Data Fig. 1: Cohort selection and data acquisition pipeline.

This study includes a total of 199 participants with ACS and 970 non-ACS individuals. Each cell shows the number of individuals who were profiled for the corresponding omic platform indicated on the left. Colored bars connecting cells represent the number of overlapping individuals. For example, there were 169 non-ACS individuals that were profiled both for serum metabolomics using the Metabolon platform and for microbiome composition. The 156 samples of individuals with ACS that were profiled using the Metabolon platform are the first to be enrolled in this study. The 473 samples of non-ACS individuals that were profiled using the Metabolon platform, were profiled as part of our previous study (Bar et al. 2020). All samples of individuals with ACS (n = 191) and of non-ACS individuals (n = 961) for which we had available serum obtained during their recruitment, were profiled using the Nightingale platform. While microbiome data were available for all individuals with and without ACS, we only considered samples for which the collection, DNA extraction and sequencing procedures were identical (n = 199 for ACS; n = 340 for non-ACS). Differential abundance analysis was performed based on subcohorts resulting from 1:1 matching for age, sex, BMI, DM, and smoking status. ACS, Acute Corony Syndrome; BMI Body Mass Index; DM, Diabetes Mellitius.